Tuesday, October 13, 2026

USD/EUR Bullish By 1% In The Last 21 Sessions

ViaNews Editorial Team

February 12, 2024

USD/EUR Bullish By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.91% for the last 21 sessions. At 15:12 EST on Monday, 12 February, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 4.634% up from its 52-week low and 3.03% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.01%, 0.10%, and 0.32%, respectively.

USD/EUR's highest amplitude of average volatility was 0.17% (last week), 0.25% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd advances to one-week top on softer usd, upside potential seems limited. According to FXStreet on Monday, 12 February, "The EUR/USD pair loses traction following an early uptick to the 1.0800 mark, or over a one-week high on Monday and drops to a fresh daily low during the first half of the European session. ", "Apart from this, the underlying bullish sentiment across the global equity markets turns out to be another factor capping gains for the safe-haven buck and acts as a tailwind for the EUR/USD pair. "
  • Eur/usd gains ground near 1.0800, ZEW survey, US CPI data eyed. According to FXStreet on Monday, 12 February, "The EUR/USD pair attracts some buyers near 1.0800 during the early Asian trading hours on Monday. "
  • Eur/usd slumps amid ecb’s dovish signals ahead of US CPI. According to FXStreet on Monday, 12 February, "Over the weekend, comments by ECB's Governing Council Panetta fueled speculation that Lagarde and Co. might cut rates earlier than the US Federal Reserve (Fed), opening the door for further EUR/USD downside. ", "On the US, February's Consumer Price Index (CPI) figures could move the needle in the EUR/USD pair. "
  • Eur/usd price analysis: could test psychological barrier at 1.0800 ahead of 14-day EMA. According to FXStreet on Monday, 12 February, "On the downside, the EUR/USD pair has immediate support at the psychological level of 1.0750, with further support at the previous week's low of 1.0722, observed on February 6. ", "A firm break above the EMA could intensify upward momentum for the EUR/USD pair, targeting the 23.6% Fibonacci retracement level at 1.0821, along with the significant barrier at 1.0850. "
  • Eur/usd can find some support back above 1.0800 – ING. According to FXStreet on Monday, 12 February, "The holding pattern that EUR/USD has shown recently may well remain the norm in the coming weeks.", "We see some modest downside risks for the Dollar this week, and think EUR/USD can find some support back above 1.0800, although a return to the 1.0930/1.0950 area looks premature."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com